NCT04634552 2026-03-17
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
Clinical Trials
14 trialsNCT04108195 2026-03-13
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05050097 2026-03-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06577025 2026-03-13
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT03399799 2026-03-12
MonumenTAL-1
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05552222 2026-03-12
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06285318 2026-03-12
REALiTEC/TAL
Janssen-Cilag Ltd.
Recruiting
NCT03601078 2026-03-04
KarMMa-2
Celgene
Phase 2 Completed
NCT06500884 2026-02-13
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT04586426 2026-01-16
RedirecTT-1
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT05455320 2026-01-16
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT04773522 2025-10-01
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
Phase 1 Completed